2-[(2'-chloropyrimidin-4'-yl)-methylamino]ethanol | 749908-65-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[(2'-chloropyrimidin-4'-yl)-methylamino]ethanol
• 英文别名: Ethanol, 2-[(2-chloro-4-pyrimidinyl)methylamino]-；2-[(2-chloropyrimidin-4-yl)-methylamino]ethanol
• CAS: 749908-65-4
• 化学式: C₇H₁₀ClN₃O
• 分子量: 187.629
• InChiKey: MPJIGCCUUQXJPR-UHFFFAOYSA-N

物化性质

• 沸点：
  376.0±22.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  49.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(2'-chloropyrimidin-4'-yl)-methylamino]ethanol 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 2-[methyl(pyrimidin-4-yl)amino]ethanol
  参考文献：
  名称：

  WO2019238424A5

  摘要：

  公开号：

  WO2019238424A5
• 作为产物：
  描述：

  N-甲基-2-羟基乙胺 、 2,4-二氯嘧啶 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 生成 2-[(2'-chloropyrimidin-4'-yl)-methylamino]ethanol
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS
  [FR] NOUVEAUX COMPOSES

  摘要：

  这项发明涉及吡啶衍生物，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。

  公开号：

  WO2004074287A1

文献信息

• Pyrimidine derivatives as anti-diabetic agents
  申请人：UNITED ARAB EMIRATES UNIVERSITY

  公开号：US10702525B1

  公开（公告）日：2020-07-07

  The pyrimidine derivatives as anti-diabetic agents are chloropyrimidinyl derivatives having the general formula of compound 81, wherein R1 is —N(CH3)CH2CH2OH (compound 81c) or —N(H)CH2CH2OH (compound 81f) or the general formula of compound 82, wherein R2 is —N(CH3)CH2CH2OH (compound 82c) or —N(CH2CH2)2O (compound 82d), as follows: The derivatives may be used for treating diabetes in humans or animals and have demonstrated efficacy, specifically in treating type 2 diabetes. Two methods of synthesizing the pyrimidine derivatives are described herein. The method using microwaves (Method B) is a green method that can provide high yields in a short time and with high purity. The compounds act as GLP-1 receptor agonists and are more potent than conventional drugs. As such, the compounds may be used in lower doses, and, hence, have fewer side effects.

  嘧啶衍生物作为抗糖尿病药物是具有化合物81的一般公式的氯嘧啶基衍生物，其中R1为—N(CH3)CH2CH2OH（化合物81c）或—N(H)CH2CH2OH（化合物81f），或具有化合物82的一般公式，其中R2为—N(CH3)CH2CH2OH（化合物82c）或—N(CH2CH2)2O（化合物82d）。这些衍生物可用于治疗人类或动物的糖尿病，并已证明在治疗2型糖尿病方面具有疗效。本文描述了两种合成嘧啶衍生物的方法。使用微波的方法（方法B）是一种绿色方法，可以在短时间内高产率地提供高纯度。这些化合物作为GLP-1受体激动剂，并且比传统药物更有效。因此，这些化合物可以以更低剂量使用，从而减少副作用。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF
  申请人：Sekiguchi Yoshinori

  公开号：US20090036448A1

  公开（公告）日：2009-02-05

  The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涵盖了新型取代嘧啶化合物的公式（I）：这些化合物作为MCH受体拮抗剂。这些化合物在制药组合物中的用途包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症（包括贪食症和厌食症）、精神障碍（包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍（包括帕金森病、癫痫和成瘾）。
• QUINOLINE, TETRAHYDROQUINOLINE AND PYRIMIDINE DERIVATIVES AS MCH ANTAGONIST
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1464335A2

  公开（公告）日：2004-10-06

  The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及式（I）化合物 其中 Q 为 作为 MCH 受体拮抗剂的化合物。这些组合物可用于药物组合物中，其用途包括预防或治疗改善记忆功能、睡眠和唤醒、焦虑、抑郁、情绪障碍、癫痫发作、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗塞、暴饮暴食症（包括贪食症）、厌食症、心肌梗塞、暴食症（包括贪食症）、厌食症、精神障碍（包括躁狂抑郁症）、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、药物滥用障碍和运动障碍（包括帕金森病）、癫痫和成瘾。
• [EN] PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF<br/>[FR] DERIVES DE PYRIMIDINE ET PROCEDES DE TRAITEMENT LIES A L'UTILISATION DE CEUX-CI
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2005095357A3

  公开（公告）日：2006-01-19